Pharmaceuticals

Factor XII Inhibitors Industry Poised for Rapid Growth, Forecast to Touch $2.34 Billion by 2030 at 10.8% CAGR

February 16, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the factor xii inhibitors market from 2026–2035 with trusted insights from The Business Research Company

How is the Factor XII Inhibitors Market size predicted to change over the forecast window of 2026–2035?

The factor xii inhibitors market has seen rapid expansion in recent years. It is forecast to increase from $1.4 billion in 2025 to $1.55 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.1%. This historic growth can be ascribed to advancements in coagulation biology research, a rising prevalence of thrombotic disorders, the constraints of traditional anticoagulants, initial clinical successes with fxii inhibition, and increasing investment in rare and specialty therapeutics.

The factor xii inhibitors market size is anticipated to experience swift expansion in the coming years. It is projected to reach $2.34 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.8%. This growth during the forecast period is driven by factors such as the proliferation of late-stage clinical trials, a rising demand for safer antithrombotic therapies, increasing adoption of precision medicine, growing regulatory support for novel anticoagulants, and the expansion of fxii inhibitors into inflammatory indications. Significant trends identified for the forecast period include the increasing development of non-bleeding anticoagulant therapies, a rising focus on targeted coagulation pathway modulation, expanding clinical evaluation of fxii selective inhibitors, the broadening application of RNA-based and peptide therapeutics, and an enhanced utilization of precision drug design.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30278&type=smp

Which Drivers Are Contributing To The Expansion Of The Factor XII Inhibitors Market?

The growing occurrence of thrombotic disorders is anticipated to fuel expansion in the factor XII inhibitors market. These thromboembolic conditions involve blood clot formation in veins or arteries, potentially obstructing blood flow and leading to serious health issues. The increase in thromboembolic disorders is linked to a rise in sedentary lifestyles, contributing to poor blood circulation and a greater chance of clot development. Factor XII inhibitors address thrombotic disorders by impeding abnormal clot formation via the contact activation pathway, without disrupting normal hemostasis. This mechanism enables effective management of thrombosis with a reduced risk of bleeding. For example, as reported by the Centers for Disease Control and Prevention (CDC), a US-based government agency, in January 2025, around 900,000 individuals in the United States suffer from venous thromboembolism, with an estimated 60,000-100,000 Americans die annually, and many others experiencing enduring complications. Consequently, the increasing prevalence of thrombotic disorders is propelling the growth of the Factor XII inhibitors market.

What Segment Classifications Make Up The Factor XII Inhibitors Market?

The factor xii inhibitors market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibodies, Small Molecule Inhibitors, Other Drug Types

2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration

3) By Application: Hereditary Angioedema, Thrombosis, Inflammatory Disorders, Other Applications

4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Bispecific Monoclonal Antibodies, Single-Chain Variable Fragment (scFv) Antibodies

2) By Small Molecule Inhibitors: Direct Factor XII Inhibitors, Allosteric Factor XII Inhibitors, Reversible Inhibitors, Irreversible Inhibitors, Peptidomimetic Inhibitors

3) By Other Drug Types: Peptide-Based Inhibitors, RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotides, Combination Therapies

How Are Emerging Trends Affecting The Progression Of The Factor XII Inhibitors Market?

Leading companies in the Factor XII Inhibitors market are dedicating their resources to developing innovative products, such as anti-FXIIa monoclonal antibodies, with the aim of boosting therapeutic precision and enhancing treatment effectiveness. Anti-FXIIa monoclonal antibodies are targeted biologics specifically designed to inhibit activated factor XII, thereby preventing the formation of abnormal clots while carefully maintaining normal hemostasis. For instance, in February 2025, CSL Behring GmbH, a biopharmaceutical company based in Germany, successfully obtained manufacturing and marketing authorization from Japan’s Ministry of Health, Labour and Welfare (MHLW) for their ANDEMBRY (garadacimab) subcutaneous (S.C.) injection 200 mg pens. This particular product is a novel, human anti-activated factor XII monoclonal antibody, which has been approved for the prophylactic treatment of acute attacks associated with hereditary angioedema (HAE). It operates by targeting activated factor XIIa, a crucial element in triggering HAE attacks, and is administered through a convenient subcutaneous injection pen.

Which Key Players Are Driving Competition In The Factor XII Inhibitors Market?

Major companies operating in the factor xii inhibitors market are Taylor & Francis Group, Santa Cruz Biotechnology Inc., CSL Limited, Bridge Medicines Inc., KalVista Pharmaceuticals Inc., Ovid Technologies Inc., Affinity Biologicals Inc., Lunac Therapeutics Ltd., Grantome LLC

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/global-factor-xii-inhibitors-market-report

Which Region Is Projected To Lead The Factor XII Inhibitors Market During The Forecast Period?

North America was the largest region in the factor XII inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the factor xii inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Factor XII Inhibitors Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=30278&type=smp

Browse Through More Reports Similar to the Global Factor XII Inhibitors Market 2026, By The Business Research Company

Tumor Necrosis Factor Inhibitor Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/tumor-necrosis-factor-inhibitor-drugs-global-market-report

Kinase Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/kinase-inhibitors-global-market-report

Enzyme Inhibitor Market Report 2026

https://www.thebusinessresearchcompany.com/report/enzyme-inhibitor-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795